BiotechTube
Home/Brenig Therapeutics/Iain Dukes, D. Phil.
ID

Iain Dukes, D. Phil.

Chief Business Officer

Brenig Therapeutics

Therapeutic Areas

Neurodegenerative DiseasesParkinson's Disease

Brenig Therapeutics Pipeline

DrugIndicationPhase
BT-267Parkinson's Disease (LRRK2-associated)Phase 1
BT-409Parkinson's Disease & Neuroinflammatory DisordersPreclinical

Leadership Team at Brenig Therapeutics

MM
Megan McGill, MD, PhD
Chief Executive Officer
View full Brenig Therapeutics profile